ClinicalTrials.gg

Program

Trastuzumab

Also written as “Herceptin”, “trastuzumab [Herceptin]” and “trastuzumab”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms · Colorectal Neoplasms · Neoplasms · Urologic Neoplasms, led by 20 companies.

Furthest: phase 4, since Dec 13, 201078 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche470 open or runningphase 4since Dec 13, 2010May 2, 2000none ahead
Novartis50 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Pfizer31 open or runningphase 3since Feb 14, 2022Oct 20, 2005Dec 31, 2027phase 3 · NCT05253651
Celltrion20 open or runningphase 3since Jun 11, 2014Jun 11, 2014none ahead
GlaxoSmithKline20 open or runningphase 2since Aug 31, 2007Aug 31, 2007none ahead
Prestige Biopharma20 open or runningphase 3since Dec 29, 2016Dec 29, 2016none ahead
Sanofi20 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Institute21 open or runningphase 2since Jun 27, 2007Jun 27, 2007none ahead
Tanvex BioPharma USA20 open or runningphase 3since Jun 1, 2018Jun 1, 2018none ahead
aryogen-pharmed-co10 open or runningphase 3since Nov 21, 2017Nov 21, 2017none ahead
Biocad10 open or runningphase 3since Jan 7, 2013Jan 7, 2013none ahead
cogent-biosciences-inc10 open or runningphase 1since Sep 14, 2018Sep 14, 2018none ahead
incepta-pharmaceuticals-ltd10 open or runningphase 1since Jan 12, 2025Jan 12, 2025none ahead
Jiangsu HengRui Medicine11 open or runningphase 3since Aug 14, 2026Aug 14, 2026Feb 28, 2030phase 3 · NCT07779538
meiji-seika-pharma-co-ltd10 open or runningphase 1since Mar 27, 2014Mar 27, 2014none ahead
Merck10 open or runningphase 2since May 27, 2008May 27, 2008none ahead
NovoCure10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
orano-med-llc10 open or runningphase 1since Jun 27, 2011Jun 27, 2011none ahead
Sino Biopharmaceutical10 open or runningphase 1since Mar 1, 2023Mar 1, 2023none ahead
Viatris10 open or runningphase 1since Oct 29, 2015Oct 29, 2015none ahead

Also a collaborator on its studies: Daiichi Sankyo, medivation-llc-a-wholly-owned-subsidiary-of-pfizer-inc, AbbVie, Zai Lab, nippon-kayaku-co-ltd, mds-pharma-services, mylan-gmbh and Dong-A Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Dec 1, 2008.

  1. Apr 20, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02748213 · 225 enrolled · Australia, Brazil, Canada and more
  2. Dec 29, 2016Prestige Biopharma's first study: phase 3 study in Breast NeoplasmsNew to Prestige BiopharmaPrestige Biopharma · NCT03013504 · 503 enrolled · Belarus, Bulgaria, Estonia and more
  3. Nov 21, 2017aryogen-pharmed-co's first study: phase 3 study in Breast NeoplasmsNew to aryogen-pharmed-coaryogen-pharmed-co · NCT03425656 · 108 enrolled · Iran, Islamic Republic of
  4. Dec 12, 2017Phase 2 study in Breast NeoplasmsSarah Cannon Research Institute · NCT03379428 · 34 enrolled · United States
  5. Jun 1, 2018Tanvex BioPharma USA's first study: phase 3 study in Breast NeoplasmsNew to Tanvex BioPharma USATanvex BioPharma USA · NCT03556358 · 809 enrolled · Belarus, Chile, Georgia and more
  6. Sep 14, 2018cogent-biosciences-inc's first study: phase 1 study in Breast NeoplasmsNew to cogent-biosciences-inccogent-biosciences-inc · NCT03680560 · 6 enrolled · United States
  7. Dec 13, 2018Phase 1 study in Healthy VolunteersPrestige Biopharma · NCT03776240 · 105 enrolled · Australia
  8. Sep 20, 2019Phase 3 study in Breast NeoplasmsTanvex BioPharma USA · NCT04109391 · 338 enrolled · Belarus, Chile, Georgia and more
  9. Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
  10. Feb 14, 2022Phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651 · 400 enrolled · United States, Argentina, Australia and more
  11. Mar 1, 2023Sino Biopharmaceutical's first study: phase 1 study in Breast NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05765357 · 89 enrolled · China
  12. Jan 12, 2025incepta-pharmaceuticals-ltd's first study: phase 1 study in Breast NeoplasmsNew to incepta-pharmaceuticals-ltdincepta-pharmaceuticals-ltd · NCT06886659 · 80 enrolled · Bangladesh
  13. Oct 6, 2025Phase 1 study in Healthy ParticipantsHoffmann-La Roche · NCT07214766 · 331 enrolled · United States
  14. Aug 14, 2026Jiangsu HengRui Medicine's first study: phase 3 study in Ovarian NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07779538 · 420 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Colorectal NeoplasmsPfizer · NCT05253651
  2. Feb 28, 2030Primary completion: phase 3 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT07779538

TargetBeta

ERBB2 →read by rule
“A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2)”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07779538Ovarian Neoplasms · China3RecruitingJiangsu HengRui MedicineFeb 28, 2030420
NCT07214766Healthy Participants · United States1CompletedHoffmann-La RocheJul 3, 2026331
NCT06886659Breast Neoplasms · Bangladesh1Completedincepta-pharmaceuticals-ltdDec 28, 202480
NCT05765357Breast Neoplasms · China1CompletedSino BiopharmaceuticalOct 27, 201789
NCT05253651Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerDec 31, 2027400
NCT04281576Stomach Neoplasms · Hong Kong–CompletedNovoCureJun 7, 202428
NCT04109391Breast Neoplasms · Belarus, Chile, Georgia and more3CompletedTanvex BioPharma USADec 25, 2021338
NCT03776240Healthy Volunteers · Australia1CompletedPrestige BiopharmaAug 19, 2019105
NCT03680560Breast Neoplasms · United States1Terminatedcogent-biosciences-incMar 12, 20206
NCT03556358Breast Neoplasms · Belarus, Chile, Georgia and more3CompletedTanvex BioPharma USANov 27, 2020809
NCT03379428Breast Neoplasms · United States2Active, not recruitingSarah Cannon Research InstituteJan 202534
NCT03425656Breast Neoplasms · Iran, Islamic Republic of3Completedaryogen-pharmed-coMar 6, 2018108
NCT03013504Breast Neoplasms · Belarus, Bulgaria, Estonia and more3CompletedPrestige BiopharmaApr 19, 2019503
NCT02748213Breast Neoplasms · Australia, Brazil, Canada and more2CompletedHoffmann-La RocheMar 2006225
NCT02721641Neoplasms · Australia, Belgium, China and more3CompletedHoffmann-La RocheFeb 201569
NCT02665637Healthy Volunteers · United States1CompletedCelltrionApr 201670
NCT02594761Healthy1CompletedViatrisFeb 2014132
NCT02536339Breast Neoplasms · United States2CompletedHoffmann-La RocheMay 1, 201940
NCT02419742Breast Neoplasms · India4CompletedHoffmann-La RocheJun 24, 2021110
NCT02402712Breast Neoplasms · Belgium, Bulgaria, Canada and more3CompletedHoffmann-La RocheFeb 22, 2019418
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedHoffmann-La RocheMay 31, 20191,044
NCT02213042Breast Neoplasms · United States, Argentina, Austria and more2TerminatedNovartisJun 4, 202042
NCT02194166Breast Neoplasms · Belarus, Kazakhstan3CompletedHoffmann-La RocheJul 12, 201890
NCT02162667HER2-positive Carcinoma of Breast · Argentina, Belarus, Bosnia and Herzegovina and more3CompletedCelltrionMay 26, 2016562
NCT02132949Breast Neoplasms · United States, Canada, Denmark and more2CompletedHoffmann-La RocheMar 3, 2016401
NCT02100917Neoplasms · Japan1Completedmeiji-seika-pharma-co-ltdMay 201470
NCT02091141Neoplasms · United States2CompletedHoffmann-La RocheMay 24, 2023673
NCT02040935Breast Neoplasms · Netherlands3CompletedHoffmann-La RocheSep 14, 2018128
NCT02019277Breast Neoplasms · Australia3CompletedHoffmann-La RocheNov 4, 201650
NCT02006667Urologic Neoplasms · Germany2CompletedHoffmann-La RocheJan 201013
NCT02005484Stomach Neoplasms · Austria, Germany2TerminatedHoffmann-La RocheFeb 20086
NCT02015676Breast Neoplasms · Spain2CompletedHoffmann-La RocheSep 200969
NCT02013765Urologic Neoplasms · Germany2TerminatedHoffmann-La RocheJan 20105
NCT01998906Breast Neoplasms · Austria, Germany, Italy and more3CompletedHoffmann-La RocheJul 2012330
NCT01964391Breast Neoplasms · Algeria, Morocco, Saudi Arabia and more3CompletedHoffmann-La RocheDec 22, 2016174
NCT01940497Breast Neoplasms · Italy3CompletedHoffmann-La RocheApr 5, 2016240
NCT01928615Breast Neoplasms · Austria2TerminatedHoffmann-La RocheOct 20132
NCT01926886Breast Neoplasms · Belgium, Israel3CompletedHoffmann-La RocheSep 4, 2015102
NCT01810393Breast Neoplasms · France3CompletedHoffmann-La RocheJul 17, 2019114
NCT01764022Breast Neoplasms · Belarus, India, Russian Federation and more3CompletedBiocadMar 2015225
NCT01748773Stomach Neoplasms · Turkey2CompletedHoffmann-La RocheAug 21, 201534
NCT01566721Breast Neoplasms · Albania, Algeria, Argentina and more3CompletedHoffmann-La RocheMar 10, 20152,577
NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more3TerminatedHoffmann-La RocheFeb 2015296
NCT01401166Breast Neoplasms · Canada, Denmark, France and more2CompletedHoffmann-La RocheMay 2013488
NCT01384253Breast Neoplasms · United States1Completedorano-med-llcOct 201518
NCT01363986Breast Neoplasms · Italy2TerminatedHoffmann-La RocheJun 20123
NCT01344863Healthy Volunteer · New Zealand1CompletedHoffmann-La RocheJan 2012119
NCT01301729Breast Neoplasms · China4CompletedHoffmann-La RocheJul 201432
NCT01290718Breast Neoplasms · Taiwan2TerminatedHoffmann-La RocheDec 20124
NCT01260194Stomach Neoplasms · India4TerminatedHoffmann-La RocheJan 20154
NCT01160211Breast Neoplasms · United States, Argentina, Australia and more3CompletedNovartisMar 11, 2016369
NCT01137994Breast Neoplasms2WithdrawnGlaxoSmithKlineDec 20160
NCT01130337Stomach Neoplasms · Spain2CompletedHoffmann-La RocheJun 201436
NCT01041404Stomach Neoplasms · Australia, Belgium, Brazil and more3CompletedHoffmann-La RocheJun 2010584
NCT00964704Breast Neoplasms2WithdrawnHoffmann-La RocheAug 20130
NCT00950300Breast Neoplasms · Argentina, Brazil, Canada and more3CompletedHoffmann-La RocheJul 12, 2011596
NCT00927589Solid Cancers · United States1CompletedHoffmann-La RocheFeb 201359
NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more2CompletedHoffmann-La RocheFeb 18, 201333
NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more2CompletedHoffmann-La RocheDec 201588
NCT00800436Breast Neoplasms · Australia, New Zealand1CompletedHoffmann-La RocheOct 200966

How it is read

Names in the registry

  • “Trastuzumab”, 36 entries
  • “Herceptin”, 13 entries
  • “trastuzumab [Herceptin]”, 11 entries
  • “trastuzumab”, 9 entries
  • “HD201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.